NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
14 trialsNCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT01167114 2023-11-02
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT01173523 2019-04-16
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01200238 2018-10-18
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01270880 2018-09-18
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01551693 2017-04-12
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01111838 2015-11-20
Clinical and Translational Study of STA-9090
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01273896 2015-11-20
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01677455 2015-11-05
Enchant
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT01368003 2015-09-01
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01031225 2014-09-19
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT01227018 2014-07-23
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated